A RNA-DNA hybrid aptamer for nanoparticle-based prostate tumor targeted drug delivery

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Leach, John C ^a   Wang, Andrew ^b   Ye, Kaiming ^a,c   Jin, Sha ^a,c  

^a University of Arkansas   (United States)

^b OCEAN NANOTECH LLC   (United States)

^c State University of New York   (United States)

Author keywords

Aptamer; Nanoparticle; Prostate cancer; Targeted drug delivery

Indexed keywords

APTAMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; STREPTAVIDIN; SUPER PARAMAGNETIC IRON OXIDE NANOPARTICLE APTAMER DOXORUBICIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA; DOXORUBICIN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MAGNETITE NANOPARTICLE; MEMBRANE ANTIGEN; RNA;

AGAR GEL ELECTROPHORESIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DNA RNA HYBRIDIZATION; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG SYNTHESIS; DRUG TARGETING; ENDOCYTOSIS; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MICROPLATE READER; MTT ASSAY; PROSTATE TUMOR; TRANSMISSION ELECTRON MICROSCOPY; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA; DOXORUBICIN; DRUG DELIVERY SYSTEMS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MAGNETITE NANOPARTICLES; MALE; PROSTATIC NEOPLASMS; RNA;

EID: 84961924660     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030380     Document Type: Article

References (42)

1. Kucharska, W.; Negrusz-Kawecka, M.; Gromkowska, M. Cardiotoxicity of oncological treatment in children. Adv. Clin. Exp. Med. 2012, 21, 281-288. [PubMed]
2. Senkus, E.; Jassem, J. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 2011, 37, 300-311. [CrossRef] [PubMed]
3. Jin, S.; Ye, K. Targeted drug delivery for breast cancer treatment. Recent Pat. Anticancer Drug Discov. 2013, 8, 143-153. [CrossRef] [PubMed]
4. Minotti, G.; Saponiero, A.; Licata, S.; Menna, P.; Calafiore, A.M.; Teodori, G.; Gianni, L. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin. Cancer Res. 2001, 7,1511-1515. [PubMed]
5. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006, 66, 6732-6740. [CrossRef] [PubMed]
6. Gu, X.G.; Schmitt, M.; Hiasa, A.; Nagata, Y.; Ikeda, H.; Sasaki, Y.; Akiyoshi, K.; Sunamoto, J.; Nakamura, H.; Kuribayashi, K.; et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 1998, 58, 3385-3390. [PubMed]
7. Jayasena, S.D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999, 45,1628-1650. [PubMed]
8. Gatto, B.; Cavalli, M. From proteins to nucleic acid-based drugs: The role of biotech in anti-VEGF therapy. Anticancer Agents Med. Chem. 2006, 6,287-301. [CrossRef] [PubMed]
9. Famulok, M. Oligonucleotide aptamers that recognize small molecules. Curr. Opin. Struct. Biol. 1999, 9, 324-329. [CrossRef]
10. Nimjee, S.M.; Rusconi, C.P.; Sullenger, B.A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 2005, 56, 555-583. [CrossRef] [PubMed]
11. Chu, T.C.; Marks, J.W.; Lavery, L.A.; Faulkner, S.; Rosenblum, M.G.; Ellington, A.D.; Levy, M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006, 66, 5989-5992. [CrossRef] [PubMed]
12. Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006,103, 6315-6320. [CrossRef] [PubMed]
13. Jeong, S.; Han, S.R.; Lee, Y.J.; Lee, S.W. Selection of RNA aptamers specific to active prostate-specific antigen. Biotechnol. Lett. 2010, 32, 379-385. [CrossRef] [PubMed]
14. Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 2010, 9, 537-550. [CrossRef] [PubMed]
15. McKeague, M.; Derosa, M.C. Challenges and opportunities for small molecule aptamer development. J. Nucleic Acids 2012, 2012, 748-913. [CrossRef] [PubMed]
16. Jin, S.; Ye, K. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol. Prog. 2007, 23,32-41. [CrossRef] [PubMed]
17. Steichen, S.D.; Caldorera-Moore, M.; Peppas, N.A. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2012, 48, 416-427. [CrossRef] [PubMed]
18. Sanna, V.; Sechi, M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine 2012, 8, S31-S36. [CrossRef] [PubMed]
19. Akhter, S.; Ahmad, Z.; Singh, A.; Ahmad, I.; Rahman, M.; Anwar, M.; Jain, G.K.; Ahmad, F.J.; Khar, R.K. Cancer targeted metallic nanoparticle: Targeting overview, recent advancement and toxicity concern. Curr. Pharm. Des. 2011,17,1834-1850. [CrossRef] [PubMed]
20. Huang, G.; Zhang, C.; Li, S.; Khemtong, C.; Yang, S.G.; Tian, R.; Minna, J.D.; Brown, K.C.; Gao, J. A novel strategy for surface modification of superparamagnetic iron oxide nanoparticles for lung cancer imaging. J. Mater. Chem. 2009,19, 6367-6372. [CrossRef] [PubMed]
21. Mondalek, F.G.; Zhang, Y.Y.; Kropp, B.; Kopke, R.D.; Ge, X.; Jackson, R.L.; Dormer, K.J. The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field. J. Nanobiotechnol. 2006, 4,1-9.
22. Barnes, A.L.; Wassel, R.A.; Mondalek, F.; Chen, K.; Dormer, K.J.; Kopke, R.D. Magnetic characterization of superparamagnetic nanoparticles pulled through model membranes. Biomagn. Res. Technol. 2007, 5. [CrossRef] [PubMed]
23. Beckmann, N.; Cannet, C.; Fringeli-Tanner, M.; Baumann, D.; Pally, C.; Bruns, C.; Zerwes, H.G.; Andriambeloson, E.; Bigaud, M. Macrophage labeling by SPIO as an early marker of allograft chronic rejection in a rat model of kidney transplantation. Magn. Reson. Med. 2003, 49,459-467. [CrossRef] [PubMed]
24. Rosen, J.E.; Chan, L.; Shieh, D.B.; Gu, F.X. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine 2012, 8, 275-290. [CrossRef] [PubMed]
25. Alwi, R.; Telenkov, S.; Mandelis, A.; Leshuk, T.; Gu, F.; Oladepo, S.; Michaelian, K. Silica-coated super paramagnetic iron oxide nanoparticles (SPION) as biocompatible contrast agent in biomedical photoacoustics. Biomed. Opt. Express 2012, 3, 2500-2509. [CrossRef] [PubMed]
26. Fukuda, Y.; Ando, K.; Ishikura, R.; Kotoura, N.; Tsuda, N.; Kato, N.; Yoshiya, S.; Nakao, N. Superparamagnetic iron oxide (SPIO) MRI contrast agent for bone marrow imaging: Differentiating bone metastasis and osteomyelitis. Magn. Reson. Med. Sci. 2006, 5,191-196. [CrossRef] [PubMed]
27. Tanimoto, A.; Kuribayashi, S. Hepatocyte-targeted MR contrast agents: Contrast enhanced detection of liver cancer in diffusely damaged liver. Magn. Reson. Med. Sci. 2005, 4, 53-60. [CrossRef] [PubMed]
28. Kim, Y.K.; Kwak, H.S.; Kim, C.S.; Chung, G.H.; Han, Y.M.; Lee, J.M. Hepatocellular carcinoma in patients with chronic liver disease: Comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology 2006, 238,531-541. [CrossRef] [PubMed]
29. Savranoglu, P.; Obuz, F.; Karasu, S.; Coker, A.; Secil, M.; Sagol, O.; Igci, E.; Dicle, O.; Astarcioglu, I. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin. Imaging 2006,30,377-381. [CrossRef] [PubMed]
30. Mack, M.G.; Balzer, J.O.; Straub, R.; Eichler, K.; Vogl, T.J. Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. Radiology 2002, 222, 239-244. [CrossRef] [PubMed]
31. Bagalkot, V.; Zhang, L.; Levy-Nissenbaum, E.; Jon, S.; Kantoff, P.W.; Langer, R.; Farokhzad, O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7, 3065-3070. [CrossRef] [PubMed]
32. Kolishetti, N.; Dhar, S.; Valencia, P.M.; Lin, L.Q.; Karnik, R.; Lippard, S.J.; Langer, R.; Farokhzad, O.C. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc. Natl. Acad. Sci. USA 2010,107,17939-17944. [CrossRef] [PubMed]
33. Mathews, D.H.; Sabina, J.; Zuker, M.; Turner, D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 1999, 288, 911-940. [CrossRef] [PubMed]
34. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003, 31, 3406-3415. [CrossRef] [PubMed]
35. Lupold, S.E.; Hicke, B.J.; Lin, Y.; Coffey, D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002, 62,4029-4033. [PubMed]
36. Bagalkot, V.; Farokhzad, O.C.; Langer, R.; Jon, S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 2006,45, 8149-8152. [CrossRef] [PubMed]
37. Fan, P.; Suri, A.K.; Fiala, R.; Live, D.; Patel, D.J. Molecular recognition in the FMN-RNA aptamer complex. J. Mol. Biol. 1996, 258,480-500. [CrossRef] [PubMed]
38. Geinguenaud, F.; Souissi, I.; Fagard, R.; Lalatonne, Y.; Motte, L. Easily controlled grafting of oligonucleotides on gammaFe2O3 nanoparticles: Physicochemical characterization of DNA organization and biological activity studies. J. Phys. Chem. B 2014,118,1535-1544. [CrossRef] [PubMed]
39. Jalalian, S.H.; Taghdisi, S.M.; Shahidi Hamedani, N.; Kalat, S.A.; Lavaee, P.; Zandkarimi, M.; Ghows, N.; Jaafari, M.R.; Naghibi, S.; Danesh, N.M.; et al. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur. J. Pharm. Sci. 2013, 50,191-197. [CrossRef] [PubMed]
40. Yu, M.K.; Kim, D.; Lee, I.H.; So, J.S.; Jeong, Y.Y.; Jon, S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011, 7, 2241-2249. [CrossRef] [PubMed]
41. Min, K.; Jo, H.; Song, K.; Cho, M.; Chun, Y.S.; Jon, S.; Kim, W.J.; Ban, C. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA+ and PSMA_ prostate cancers. Biomaterials 2011, 32, 2124-2132. [CrossRef] [PubMed]
42. Sato, Y.; Yamauchi, N.; Takahashi, M.; Sasaki, K.; Fukaura, J.; Neda, H.; Fujii, S.; Hirayama, M.; Itoh, Y.; Koshita, Y.; et al. In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J. 2000,14, 2108-2118. [CrossRef] [PubMed]